
Arrowhead Pharmaceuticals Hits New 52-Week High of $46.89
2025-11-26 16:24:34Arrowhead Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 3,756 million, is noted for its innovative approaches in the biotech sector, despite facing financial challenges and a loss-making position.
Read More
Arrowhead Pharmaceuticals Hits Day High with 9.42% Surge in Stock Price
2025-11-25 16:39:04Arrowhead Pharmaceuticals, Inc. saw a notable rise in stock performance on November 24, 2025, with significant gains over the past week and month. Despite strong year-to-date growth, the company faces challenges such as negative EBITDA and a high price-to-book ratio, reflecting a complex financial situation.
Read More
Arrowhead Pharmaceuticals Hits New 52-Week High of $44.80
2025-11-25 16:17:39Arrowhead Pharmaceuticals, Inc. has achieved a new 52-week high, reflecting its strong performance in the pharmaceuticals and biotechnology sector. The company has experienced significant growth over the past year, despite being in a loss-making position and not offering dividends, indicating a focus on reinvestment and expansion.
Read More
Arrowhead Pharmaceuticals Hits New 52-Week High of $43.69
2025-11-03 17:01:37Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 43.69 on October 31, 2025, reflecting strong growth in the Pharmaceuticals & Biotechnology industry. Despite its loss-making status and challenges in profitability, the company has shown significant performance improvement over the past year, outpacing broader market gains.
Read More
Arrowhead Pharmaceuticals Hits New 52-Week High at $43.33
2025-10-31 16:03:22Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 43.33 on October 30, 2025, reflecting strong performance in the pharmaceuticals sector. The company has seen a 72.62% growth over the past year, despite being loss-making, and has a market capitalization of USD 3,756 million.
Read More
Arrowhead Pharmaceuticals Hits New 52-Week High of $40.74
2025-10-30 18:20:22Arrowhead Pharmaceuticals has achieved a new 52-week high of USD 40.74, significantly up from its low of USD 9.57. The company, with a market cap of approximately USD 3,756 million, has seen a 64.38% stock increase over the past year, despite ongoing financial losses and a premium valuation.
Read More
Arrowhead Pharmaceuticals Hits New 52-Week High of $39.42
2025-10-07 21:40:29Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 39.42 on October 6, 2025, reflecting a 53.0% increase over the past year. With a market capitalization of USD 3,756 million, the company remains in a loss-making position, highlighting its unique financial structure within the biotechnology sector.
Read More
Arrowhead Pharmaceuticals Hits New 52-Week High of $36.24
2025-10-06 17:25:10Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 36.24 on October 3, 2025, reflecting a substantial increase over the past year. With a market capitalization of USD 3,756 million, the company remains in a loss-making position, indicated by its financial metrics and premium valuation.
Read More
Arrowhead Pharmaceuticals Hits New 52-Week High of $35.40
2025-10-02 22:28:28Arrowhead Pharmaceuticals, Inc. achieved a new 52-week high of USD 35.40 on October 1, 2025, reflecting strong performance in the Pharmaceuticals and Biotechnology sector. The company has seen a 42.84% growth over the past year, significantly outperforming the S&P 500, despite being loss-making.
Read More





